DE69814394T2 - Verwendung von levobupivacain - Google Patents
Verwendung von levobupivacain Download PDFInfo
- Publication number
- DE69814394T2 DE69814394T2 DE69814394T DE69814394T DE69814394T2 DE 69814394 T2 DE69814394 T2 DE 69814394T2 DE 69814394 T DE69814394 T DE 69814394T DE 69814394 T DE69814394 T DE 69814394T DE 69814394 T2 DE69814394 T2 DE 69814394T2
- Authority
- DE
- Germany
- Prior art keywords
- levobupivacaine
- surgery
- bupivacaine
- dose
- block
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims abstract description 65
- 229960004288 levobupivacaine Drugs 0.000 claims abstract description 64
- 238000001356 surgical procedure Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims description 20
- 206010002091 Anaesthesia Diseases 0.000 claims description 13
- 230000037005 anaesthesia Effects 0.000 claims description 13
- LEBVLXFERQHONN-MRXNPFEDSA-N dextrobupivacaine Chemical compound CCCCN1CCCC[C@@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-MRXNPFEDSA-N 0.000 claims description 4
- 230000000399 orthopedic effect Effects 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010019909 Hernia Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 238000007486 appendectomy Methods 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 238000002297 emergency surgery Methods 0.000 claims 1
- 238000002682 general surgery Methods 0.000 claims 1
- 238000009802 hysterectomy Methods 0.000 claims 1
- 210000002050 maxilla Anatomy 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000007483 tonsillectomy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 38
- 229960003150 bupivacaine Drugs 0.000 description 33
- 229940079593 drug Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 230000001953 sensory effect Effects 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000003589 local anesthetic agent Substances 0.000 description 7
- 230000003444 anaesthetic effect Effects 0.000 description 6
- 210000003461 brachial plexus Anatomy 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 5
- 208000003663 ventricular fibrillation Diseases 0.000 description 5
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 238000012084 abdominal surgery Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical class CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000003540 papillary muscle Anatomy 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 231100000457 cardiotoxic Toxicity 0.000 description 2
- 230000001451 cardiotoxic effect Effects 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002692 epidural anesthesia Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960001549 ropivacaine Drugs 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010069571 Atrioventricular dissociation Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003099 femoral nerve Anatomy 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Electrotherapy Devices (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9715462.9A GB9715462D0 (en) | 1997-07-22 | 1997-07-22 | levobupivacaine and its use |
| GB9715462 | 1997-07-22 | ||
| GBGB9722022.2A GB9722022D0 (en) | 1997-10-17 | 1997-10-17 | Levobupivacaine and its use |
| GB9722022 | 1997-10-17 | ||
| GBGB9810427.6A GB9810427D0 (en) | 1998-05-14 | 1998-05-14 | Levobupivacaine and its use |
| GB9810427 | 1998-05-14 | ||
| PCT/GB1998/002170 WO1999004772A2 (en) | 1997-07-22 | 1998-07-21 | Use of levobupivacaine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69814394D1 DE69814394D1 (de) | 2003-06-12 |
| DE69814394T2 true DE69814394T2 (de) | 2004-03-11 |
Family
ID=27268945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69814394T Expired - Lifetime DE69814394T2 (de) | 1997-07-22 | 1998-07-21 | Verwendung von levobupivacain |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6069155A (enExample) |
| EP (1) | EP0998287B1 (enExample) |
| JP (1) | JP2001510795A (enExample) |
| AT (1) | ATE239474T1 (enExample) |
| AU (1) | AU739510B2 (enExample) |
| BR (1) | BR9802537A (enExample) |
| CA (1) | CA2294921C (enExample) |
| DE (1) | DE69814394T2 (enExample) |
| DK (1) | DK0998287T3 (enExample) |
| ES (1) | ES2198731T3 (enExample) |
| PT (1) | PT998287E (enExample) |
| WO (1) | WO1999004772A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376754B1 (en) * | 1997-03-07 | 2002-04-23 | Asgrow Seed Company | Plants having resistance to multiple herbicides and its use |
| AU752802C (en) | 1997-11-14 | 2006-04-13 | Pacira Pharmaceuticals, Inc. | Production of multivesicular liposomes |
| WO2000003660A1 (en) | 1998-07-17 | 2000-01-27 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| WO2001070322A1 (en) * | 2000-03-24 | 2001-09-27 | Stephen Brushey | Anesthesia conduction catheter |
| US7805188B2 (en) * | 2000-03-24 | 2010-09-28 | Micor, Inc. | Anesthesia conduction catheter for delivery of electrical stimulus |
| BR0002246A (pt) * | 2000-04-06 | 2003-04-15 | Cristalia Prod Quimicos Farm | Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis |
| WO2002096368A2 (en) * | 2001-05-31 | 2002-12-05 | Skyepharma Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
| US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
| AU2002359407B2 (en) * | 2001-11-14 | 2008-02-28 | Durect Corporation | Catheter injectable depot compositions and uses thereof |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| CN1684663A (zh) | 2002-07-31 | 2005-10-19 | 阿尔萨公司 | 可注射的多模式聚合物储库组合物以及其用途 |
| WO2004012703A1 (en) * | 2002-07-31 | 2004-02-12 | Alza Corporation | Injectable depot compositions and uses thereof |
| WO2004060147A2 (en) * | 2002-12-31 | 2004-07-22 | The Board Of Trustees Of The University Of Illinois | Tissue and organ preservation, protection and resuscitation |
| US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| WO2015088990A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| WO2021146215A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| CA3203561A1 (en) | 2021-01-12 | 2022-07-21 | Adrian Neil Verity | Sustained release drug delivery systems and related methods |
| US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12151024B2 (en) | 2021-01-22 | 2024-11-26 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12285419B2 (en) | 2021-10-14 | 2025-04-29 | Pacira Pharmaceuticals, Inc. | Bupivacaine multivesicular liposome formulations and uses thereof |
| US12070454B1 (en) | 2022-05-05 | 2024-08-27 | Pfof Llc | Anesthetic nerve block and method |
| CN119677554A (zh) | 2022-05-05 | 2025-03-21 | 普络夫有限责任公司 | 麻醉神经阻滞和方法 |
| US12156940B1 (en) | 2024-05-20 | 2024-12-03 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12251472B1 (en) | 2024-05-20 | 2025-03-18 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12280149B1 (en) | 2024-05-20 | 2025-04-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695576A (en) * | 1984-07-09 | 1987-09-22 | Astra Lake Medel Aktiebolag | L-N-n-propylpipecolic acid-2,6-xylidide |
| AU694453B2 (en) * | 1993-10-13 | 1998-07-23 | Darwin Discovery Limited | Analgesic agent and its use |
| GB9321061D0 (en) * | 1993-10-13 | 1993-12-01 | Chiroscience Ltd | Analgestic agent and its use |
| US5849763A (en) * | 1993-10-13 | 1998-12-15 | Darwin Discovery Limited | Use of levobupivacaine as an anesthetic agent |
| CA2216583C (en) * | 1995-04-13 | 2007-10-30 | Chiroscience Limited | Levobupivacaine and its use as an anaesthetic in pregnant women |
| GB9704352D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
-
1998
- 1998-07-21 AT AT98935176T patent/ATE239474T1/de active
- 1998-07-21 EP EP98935176A patent/EP0998287B1/en not_active Expired - Lifetime
- 1998-07-21 ES ES98935176T patent/ES2198731T3/es not_active Expired - Lifetime
- 1998-07-21 BR BR9802537A patent/BR9802537A/pt not_active Application Discontinuation
- 1998-07-21 WO PCT/GB1998/002170 patent/WO1999004772A2/en not_active Ceased
- 1998-07-21 AU AU84528/98A patent/AU739510B2/en not_active Expired
- 1998-07-21 DE DE69814394T patent/DE69814394T2/de not_active Expired - Lifetime
- 1998-07-21 JP JP2000503831A patent/JP2001510795A/ja active Pending
- 1998-07-21 PT PT98935176T patent/PT998287E/pt unknown
- 1998-07-21 DK DK98935176T patent/DK0998287T3/da active
- 1998-07-21 CA CA002294921A patent/CA2294921C/en not_active Expired - Lifetime
- 1998-07-22 US US09/120,822 patent/US6069155A/en not_active Expired - Lifetime
-
2001
- 2001-10-01 US US09/969,412 patent/US6514994B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT998287E (pt) | 2003-09-30 |
| JP2001510795A (ja) | 2001-08-07 |
| ES2198731T3 (es) | 2004-02-01 |
| US6514994B2 (en) | 2003-02-04 |
| EP0998287B1 (en) | 2003-05-07 |
| DK0998287T3 (da) | 2003-09-01 |
| AU8452898A (en) | 1999-02-16 |
| AU739510B2 (en) | 2001-10-11 |
| EP0998287A2 (en) | 2000-05-10 |
| US6069155A (en) | 2000-05-30 |
| US20020016338A1 (en) | 2002-02-07 |
| CA2294921A1 (en) | 1999-02-04 |
| WO1999004772A2 (en) | 1999-02-04 |
| WO1999004772A3 (en) | 1999-04-08 |
| DE69814394D1 (de) | 2003-06-12 |
| CA2294921C (en) | 2009-04-07 |
| ATE239474T1 (de) | 2003-05-15 |
| BR9802537A (pt) | 1999-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU739510B2 (en) | Levobupivacaine and its use | |
| DE69402330T2 (de) | Analgetisches mittel und dessen verwendung | |
| DE69900249T2 (de) | Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie | |
| DE69830178T2 (de) | Wirstoffmischung in vagal-induzierter asystolie | |
| DE69434416T2 (de) | Präparate auf purinbasis | |
| DE69403969T2 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
| DE69119495T2 (de) | Verfahren zur Behandlung der Parkinson'schen Erkrankung durch Anwendung des ATP-sensitiven Kaliumkanalblockers Chinin | |
| DE69814851T2 (de) | Verwendung von levobupivacaine in gesichtschirugie | |
| DE3218761C2 (enExample) | ||
| DE69106586T2 (de) | Verwendung von Baclofen zur Herstellung von Arzneimitteln zur Behandlung von Angina pectoris. | |
| DE69118859T2 (de) | Behandlung von Schlafstörungen unter Verwendung bestimmter Antidepressiva, z.B. Nefazodon | |
| US6103741A (en) | Analgesic agent and its use | |
| DE69224069T2 (de) | Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält | |
| EP0413171A1 (de) | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung | |
| DE69814852T2 (de) | Verwendung von levobupivacaine in der pediatrischen chirurgie | |
| DE69114470T2 (de) | Komposition für die behandlung von augenschmerzen. | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE60317935T2 (de) | Alpha-aminoamid-derivate als mittel gegen migräne | |
| DE69232516T2 (de) | Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung | |
| DE69628743T2 (de) | Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen | |
| DE69937574T2 (de) | Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen | |
| CH658595A5 (de) | Retinoprotektor zur behandlung von augenerkrankungen. | |
| DE69430427T2 (de) | Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade | |
| DE69904297T2 (de) | Neue verwendung von ropivacain zur schmerzbehandlung | |
| DE69919789T2 (de) | Loratadin zur Verwendung als Antiarrhythmikum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |